Topic:

R&D

Latest Headlines

Latest Headlines

UPDATED: Setback forces Novo Nordisk to abandon anti-inflammatory R&D work, affecting 400 staffers

Among all the pharma companies, Novo Nordisk always stood out for its relentless R&D focus on diabetes and obesity. Today, the Danish company amped up that concentration another notch, jettisoning a group of clinical programs and winding down its work in anti-inflammatory treatments. And the pharma player added that the move would hit some 400 staffers, with close to half likely to lose their jobs at Novo.

Cenix lands an early-phase deal with BASF's Metanomics

German CRO Cenix BioScience has signed a deal with a BASF subsidiary to help ferret out new biomarkers, focusing on the growing field of metabolomics.

CRO Onyx signs up to help CRUK handle cancer R&D

Cancer Research UK has enlisted contract drugmaker Onyx Scientific to pitch in on some of its early research projects, handling development and manufacturing for clinical trials.

Boehringer to stay focused on porcine type 2 vaccine; dropping its RTU program

Boehringer Ingelheim said it will end research into developing a porcine circovirus type 2 ready-to-use vaccine combination to focus its attention on its PCV2 Mycoplasma hyopneumoniae vaccine.

Berg backs AI-driven discovery platform to save time, money in R&D

With its big claims about how artificial intelligence can slash drug development timelines and a lead candidate based on a coenzyme best known as a dietary supplement, Berg is always likely to provoke skepticism. But the company is sticking to its guns, with President and CTO Niven Narain pointing to early drug discovery successes as evidence of its legitimacy.

UPDATED: Cabozantinib flops against prostate cancer, forcing big job cuts at Exelixis

Late on Monday evening Exelixis put out the word that its crucial late-stage study of cabozantinib flunked a comparison study with prednisone for castration-resistant prostate cancer, triggering a restructuring that will eliminate 70% of the jobs at the biotech.

Amazon's meeting with FDA starts the rumor mill turning

Amazon is the latest tech giant to consider expanding into healthcare, but details of the online retailer's plans are sketchy.

Sanofi, Regeneron point to potential heart benefit in PCSK9 data dump

The development team from Sanofi and Regeneron journeyed to the ESC Congress in Barcelona this weekend to detail the impact their late-stage PCSK9 drug alirocumab has on bad cholesterol, drawing some high-profile attention for a batch of preliminary numbers suggesting a trend toward lower cardiovascular risks.

Novartis' LCZ696 kindles megablockbuster projections with impressive PhIII heart data

Novartis told the world back in March that its experimental heart drug LCZ696 had delivered the goods early in a pivotal study, allowing for a quick wrap of the Phase III trial. And today the pharma giant painted in the numbers, completing the late-stage picture for a closely watched therapy that has the potential to rival the most successful drug franchises now on the market.

FDA clears Glaxo Ebola vaccine for speedy human trials

GlaxoSmithKline's vaccine candidate for the deadly Ebola virus is ready to roll in human trials.